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Abstract The immune system regulates angiogenesis in
cancer by way of both pro- and antiangiogenic activities. A
bidirectional link between angiogenesis and the immune
system has been clearly demonstrated. Most antiangiogenic
molecules do not inhibit only VEGF signaling pathways
but also other pathways which may affect immune system.
Understanding of the role of these pathways in the regu-
lation of immunosuppressive mechanisms by way of
specific inhibitors is growing. Renal cell carcinoma (RCC)
is an immunogenic tumor in which angiogenesis and
immunosuppression work hand in hand, and its growth is
associated with impaired antitumor immunity. Given the
antitumor activity of selected TKIs in metastatic RCC
(mRCC), it seems relevant to assess their effect on the
immune system. The confirmation that TKIs improve cell
cytokine response in mRCC provides a basis for the
rational combination and sequential treatment of TKIs and
immunotherapy.
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Introduction
Angiogenesis, which is regulated by a fine balance between
pro- and antiangiogenic signals, represents a key event in
the development of tumors. In the absence of oxygen in the
tumor nucleus, expression of some transcriptional factors,
such as hypoxia inducible factor (HIF), is induced. HIF
enhances the expression of pro-angiogenic factors such as
vascular endothelial growth factor (VEGF) and platelet-
derived growth factor (PDGF). VEGF is an important
inducer of angiogenesis, the expression of which is also
controlled by different oncoproteins such as epidermal
growth factor (EGF), K-ras, and PDGF, among others
[1, 2].
Immune dysfunction has been well documented in
cancer patients, including those affected by renal cell car-
cinoma (RCC) [3–5]. RCC patients present a shift from a
type-1-mediated CD4? T cell response producing inter-
feron gamma (IFNc) to a type-2 cytokine response,
involving interleukins (IL) 4, 5, and 10. Type-1-mediated
CD4? T cell response is critical for the development of
effective antitumor immunity, while type-2 cytokine
response typically mediates humoral immunity. More
specifically, tumor-specific T cell response to tumor-asso-
ciated antigens MAGE-6 and EphA2 is characterized by a
predominance of T cells synthesizing IL5 and IL4, together
with reduced levels or a complete absence of T lympho-
cytes expressing IFNc [6, 7]. However, the diminished
type-1 response in RCC patients is not limited to MAGE-6
and EphA2-specific CD4? T cells. It has also been reported
that after undergoing primary tumor excision and/or
immunotherapy and presenting a disease-free period,
IFNc-producing type-1 CD4? T cells prevail in RCC
patients, suggesting that tumor environment may promote a
type-2 response [6]. In advanced stages of RCC, the
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peripheral blood lymphocyte response also changes from
predominantly type 1 to type 2 after polyclonal activation
[8].
Antiangiogenic molecules can inhibit many immuno-
suppressive mechanisms, such as regulatory T (Treg) cells,
myeloid-derived suppressor cells (MDSCs), immunosup-
pressive cytokines, and others. Besides, they play a crucial
role in inducing an efficient immunostimulatory antitumor
response. In this respect, emerging evidence indicates that
tyrosine kinase inhibitors (TKIs) modulate hematopoiesis
and immune functions [9], and their effect on myelopoiesis
depends on their different selectivity for c-kit and FLT3
receptors, expressed on hematopoietic stem cells and pre-
cursor cells [9, 10].
Proangiogenic factors
When proangiogenic factors are induced by hypoxia or
oncoproteins, the balance between pro- and antiangiogenic
factors is deregulated, resulting in proliferation and
migration of vascular cells and the formation of new blood
vessels. The structure of new blood vessels is altered,
resulting in distorted and enlarged vessels, increased per-
meability, irregular blood flow, and microhemorrhages in
the tumor. This deregulation also leads to reduced lym-
phocyte infiltration in the tumor [11]. Some of these
proangiogenic molecules, such as VEGF, placental growth
factor (PlGF), and hepatocyte growth factor (HGF) are able
to modulate immunity [12, 13].
VEGF-A is also involved in the induction of tumor
immunosuppression at different levels. First, tumor-derived
VEGF-A can inhibit transcription nuclear factor-jB (NF-
jB) via VEGFR-1 signaling and thereby prevent dendritic
cell (DC) maturation [13, 14]. In cancer patients, increases
in VEGF plasma levels are also correlated with the pres-
ence of immature DCs and immature myeloid cells in
peripheral blood [15]. In tumor-bearing mice and meta-
static colorectal cancer patients, VEGF-A can directly
activate Treg cell proliferation in a VEGFR-2-dependent
manner [16], as well as contributing to tumor-associated
macrophage (TAM) development, by inducing the
recruitment of monocytes/macrophages to the tumor. It has
also been reported that VEGF-A administration decreases
the proportion and number of splenic T cells and sup-
presses their function [17].
PlGF prevents DC differentiation [13] and inhibits the
capacity of human myeloid-derived DCs to stimulate a Th1
response, as demonstrated in some in vitro experiments
[18]. HGF, produced by a large number of tumors, such as
carcinomas, soft tissue sarcoma, and hematopoietic
malignancies, is implicated in tumor angiogenesis [19],
while its receptor c-met is not only expressed by diverse
tumor cells, but also present on the surface of immune cells
such as DCs [20].
Immunosuppressive cells
Myeloid-derived suppressor cells
MDSCs are immature myeloid cells that, in chronic
inflammatory conditions, fail to eventually differentiate
into granulocytes, macrophages or DCs [21, 22]. MDSCs
comprise a very heterogeneous population that can present
widely distinct phenotypical characteristics [23–25],
although they always exhibit remarkable immunosuppres-
sive and tumorigenic activities [23–26].
Two subsets of human MDSCs can be distinguished:
granulocytic MDSCs (Lin-HLA-DR-CD33? or CD11b?
CD14-CD15?) and monocytic MDSCs (14?HLA-DRneg/lo
or CD11b? CD14?HLD-DRneg/lo) [24–27].
MDSC tumorigenic activity includes the secretion of
angiogenic factors promoting neoangiogenesis [28], the
production of growth factors, matrix metalloproteinases
and cytokines that activate Th2 type and Treg cells [29–31]
and the deprivation of arginine and cysteine necessary for
T cell functions [25, 32]. MDSCs also enhance the pro-
duction of nitric oxide and reactive oxygen species, causing
T cell receptor (TCR) nitration or T cell apoptosis [25], the
expression of membrane-bound transforming growth factor
beta 1 (TGF-b1), inducing anergy of immune effector cells
[25, 33] and a down-regulation of the TCR-chain expres-
sion, disabling the capacity of T cells to transmit activation
signals [25].
In summary, MDSCs create favorable conditions for
tumorigenesis, tumor growth, metastasis, and neoangio-
genesis, and confer tumor resistance to antiangiogenic
drugs [34]. These processes are tightly interrelated and are
governed by MDSC-derived mediators, such as apoptotic
factors (TNF-a), interleukins (IL-1, IL-6), growth factors
[TGF-b, VEGF, basic fibroblast growth factor (bFGF)],
and HIF-1a. The presence of MDSCs has been described in
RCC patients and can account for their impaired immune
response [35].
Therefore, understanding the mechanism and checkpoint
regulators of MDSC-tumor interaction is critically impor-
tant to overcome immunosuppression and to achieve better
therapeutic effects in cancer patients.
Dendritic cells
DCs are efficient antigen-presenting cells that can present
tumor-specific antigens and subsequently activate a speci-
fic antitumor T cell response in vivo. Immature DCs pro-
cess antigens and then mature to activated DCs,
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subsequently eliciting a productive immune response. DCs
are not often found in tumor infiltrates [36], although
sometimes they can be found in an immature state, unable
to induce an effective immune response [37].
DCs have been shown to induce immune tolerance in
several ways, including T cell deletion [38, 39], induction
of T cell unresponsiveness [40] and Treg activation
[41–43]. Immature DCs have been shown to silence
immunity and to induce immune tolerance by inhibiting T
cells or activating Treg cells [41] through tumor-derived
factors, such as VEGF, IL-6, and macrophage colony-
stimulating factor [44, 45].
Once activated, antigen-loaded DCs activate antigen-
specific immunity [46], through T cell proliferation and
differentiation into helper and effector cells. DCs also play
an important role in humoral immunity, as they directly
interact with B cells [47] and present unprocessed antigens
[48].
Numerous studies in humans have concluded that DCs
can infiltrate and fight tumors, through at least two path-
ways: directly via DC-dependent tumor cytokines and
indirectly, via the induction of potent cytotoxic T-lym-
phocyte (CTL) responses.
In the context of RCC, it is important to highlight that
carcinogenic cells have been described as inhibiting DC
maturation, DC-induced T cell activation, and antitumor
CTL response, by releasing IL-6 and VEGF [49].
Besides, increased tumor infiltration of DCs has been
shown as a predictor for treatment response and an
outcome in mRCC patients treated with immunotherapy
[50].
T regulatory cells
There is growing evidence that CD4? CD5? Treg cells
may play an important role in suppressing the development
of antitumor immunity in cancer patients [51] and that the
number of Treg cells is increased in tumor sites and/or the
peripheral blood of patients with advanced tumors [52–54].
Natural killer cells
Natural killer (NK) cells are part of the hematopoietic
system and are derived from CD34? hematopoietic pro-
genitor cells [55–57]. NK cells recognize and lyse tumor
cells with no need for maturation or major histocompati-
bility complex recognition; besides, they are thought to be
involved in immune surveillance against cancer [58, 59].
There is also some evidence of the critical role of NK cells
in angiogenesis inhibition by IL-12-induced IFNc secre-
tion. In RCC terms, the presence of lymphocytic infiltrate
with high levels of NK cells has been described as a good
prognostic factor [60].
Monocytes/macrophages
Monocytes/macrophages represent a quantitative and
functionally important subpopulation within the tumor
microenvironment. TAMs are derived from circulating
peripheral blood monocytes attracted to the tumor site by
chemotactic factors, such as colony stimulating factor 1,
which also induce macrophage differentiation [61] and are
involved in malignant progression. TAMs mediate their
immunosuppressive activity by releasing inhibitory
cytokines such as TGF-b and enhancing the production of
IL-10 [62].
In addition, TAMs produce large amounts of VEGF and
might be responsible for the tumor angiogenic switch [63].
In RCC, the number of TAMs significantly correlates with
tumor microvessel density and VEGF levels [64].
Immune dysfunction: type 1/type 2 bias
In RCC patients, there is a shift from a type-1-mediated
CD4? T cell response producing IFNc, which is critical for
the development of effective antitumor immunity, to a
type-2 cytokine IL-4, IL-5, and IL-10 response that typi-
cally mediates humoral immunity [65].
Type-2 bias exists in T cells from mRCC patients, as
tumor-specific CD4? T cells displaying a T-helper type-2
bias have been isolated from mRCC patients [6, 7].
Additional studies have shown that a type-2 bias is present
in T cells from mRCC patients after polyclonal stimulation
of peripheral blood mononuclear cells (PBMC) with anti-
CD3/anti-CD28 antibodies [8, 66, 67]. When compared
with healthy donors, mRCC patients show a significant
reduction in the percentage of CD4? T cells expressing
intracellular IFNc, whereas the percentage of IL-4? T cells
was similar in both. Moreover, it has been demonstrated
that RCC patients whose tumor environment is biased
toward a type-1 immune response have a more favorable
prognosis [68].
Modulation of immune cells by tyrosine kinase
inhibitors
Two kinds of antiangiogenic molecules are currently
available: TKIs, which target receptors of proangiogenic
factors and block their signaling functions; and monoclonal
antibodies, which directly target circulating proangiogenic
factors or their receptors.
Immune therapy usually requires time to generate,
activate, and stimulate an antitumor immune response.
Previous reports have described how antiangiogenic treat-
ment could normalize tumor vessels as early as 2 days
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post-treatment [69, 70]. Therefore, the combined treatment
schedule should be designed to synchronize vascular nor-
malization and T cell activation. A previous study has
suggested that antiangiogenic therapy preceding vaccine
therapy has a better antitumor effect than vaccine therapy
followed by antiangiogenic treatment [71]. Recently,
immunotherapy with nivolumab showed longer overall
survival than everolimus among patients with advanced
RCC previously treated with antiangiogenic therapies [72].
A subgroup analysis of this last study found that patients
previously treated with pazopanib showed a statistically
significant increase in overall survival with nivolumab,
while patients previously treated with sunitinib showed
insignificant differences in overall survival between nivo-
lumab and everolimus. This suggests that different TKIs
might enhance subsequent immunotherapy by different
mechanisms [73]. Thus, studies comparing the efficacy of
different combination schedules might yield even better
treatment regimens in the future.
The TKIs, sunitinib, pazopanib, sorafenib, and axitinib,
have an impact not only on both tumor growth and
angiogenesis, but also on the activity and function of
immune effector cells. TKI treatment results in a dramatic
reduction of T cell proliferation, along with distinct
repercussions on cell cycle progression. Administration of
TKIs reduces absolute neutrophil [74], monocyte [75], and
lymphocyte counts [76, 77]. Of these, monocyte count
undergoes the largest proportional decrease [78]. Patients
with clinical benefit have a significantly smaller decrease in
monocyte levels during the first cycle of treatment than
patients with progressive disease [78]. A decrease in the
absolute neutrophil count was associated with longer time
to progression [79], while a decrease in total number of
lymphocytes after sunitinib treatment has shown no benefit
in terms of overall survival, when compared to patients
with stable or increased total lymphocytes count [76].
Platelets also seem to play a role in the inmune response.
Cysteine-rich protein 61(CYR61) connective tissue growth
factor nephroblastoma overexpressed 1 (CCN1) is pro-
duced by endothelium cells and platelets and coats the
internal side of the blood vessel. The increase of CCN1
amount is essential both for the recruitment of resident
monocytes and for their patrolling activity. Without pla-
telets in the blood, the CCN1 level will not rise and,
therefore, the early arrival of Ly6Clow monocytes will be
impaired and the recruitment of neutrophils abolished.
Treatments that decrease the number of platelets may
compromise the start of immune response [80]. This
reduction in immune cells counts might explain, at least in
part, some of the hematologic side effects of TKIs.
Targeting immunosuppressive cells might improve
antitumor T cell response, thereby providing a rationale for
the combination of TKIs with immunotherapy in the
treatment of RCC.
Some studies suggest that Treg cells may be involved in
modulating type-1 and type-2 cytokine response and that a
reduction in their level is associated with an increase in T
cell function as measured via IFN-c levels [77]. Likewise,
this increase in T cell function is also correlated with a
reduction in MDSC populations, suggesting that both
MDSCs and Treg cells are contributing to immune dys-
function in mRCC patients.
TKIs induce a reduction in Treg cell levels in mRCC
patients. Their effect on Treg cell levels in peripheral blood
has been examined in patients before sunitinib treatment
and on day 28 of both first and second cycles. Compared to
pretreatment values, the percentage of Treg cells was
reduced after 1 cycle, although the reduction did not reach
statistical significance. However, a negative correlation
between the decreases of Treg cells after 1 or 2 cycles of
treatment, and the increase of IFNc-producing CD4? T
cells, was shown at the end of cycle 2. A negative corre-
lation was also seen with the IFNc response of total T cells
(CD3?) population [77]. Thus, these findings may support
the fact that the greater the reduction of Treg cells fol-
lowing 1 or 2 cycles of treatment, the stronger the type-1
response after 2 cycles of treatment [77].
The results reviewed here suggest that TKIs may have
an effect on Treg cell population resulting in improved
type-1 cytokine response. One plausible explanation for
these findings is that the restoration of a type-1 IFNc
response is related to a decrease in the immunosuppressive
tumor burden.
The hypothesis that the clinical response induced by
TKIs is influenced by the degree of type-2 bias at baseline
could be explained either by an immune mechanism of this
therapeutic family or by the importance of parallel mech-
anisms of antitumor effect (TKI-induced antiangiogenic
and innate immune response).
TKIs can reverse the immune suppression caused by
Treg or MDSCs [77, 81, 82] and improve type 1 T cell
cytokine response [77, 82–84], and these immunologic
effects are currently under discussion. Moreover, the
expression of negative co-stimulatory molecules, such as
CTLA4 and PD-1 in CD4? and CD8? T cells, has also
been shown to significantly decrease in sunitinib-treated
mice [82], whereas a decrease of the T cell-mediated
immune response has been observed upon sunitinib treat-
ment in another murine model [85].
Some mechanisms that might explain the reduction of
TKI-induced Treg cells, such as MDSC inhibition [81] or
blockage of the conversion of conventional CD4? Foxp3-
T cells into CD4? Foxp3? Treg cells [86], have been
described.
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TKIs seem to modulate MDSCs in different ways, such
as: (1) inhibition of signal transducer and activator of
transcription 3 (STAT3) [87], (2) induction of monocytic
subset (Gr1lo) of MDSC proliferation, and (3) apoptosis of
the granulocytic subset (Gr1hi) of MDSCs [34]. In mRCC
patients, the proportion of all MDSC subsets (immature
lin-, monocytic CD33? CD14? DR- and granulocytic
CD33? CD15? DR-) has been shown to decrease in
peripheral blood after the first cycle of sunitinib treatment
[81]. Similarly, only patients who do not respond to
pazopanib treatment show increased MDSCs [84]. More
importantly, MDSCs, either directly or through the induc-
tion of Treg cells, are involved in the development of TKI
resistance [88].
TKIs could also regulate the expression of NK cell
ligands, activating receptors in tumor cells. Thus, sunitinib
and sorafenib induce NKG2D ligand expression, which
confers enhanced sensitivity to NK cell lysis [89, 90].
Sorafenib also inhibits spontaneous and IL-2-induced NK
effector functions [91], while axitinib has been shown to
strongly suppress T cells proliferation, which might pos-
sibly affect the expansion of tumor-specific T cells [92]. In
addition, axitinib enhances NK cell recognition and activ-
ity against RCC cells, by regulating NK cell-activating
ligand expression [93].
Sorafenib inhibits DC antigen presentation and can
stimulate primary T cell responses, by reducing the
secretion of cytokines or the expression of MHC and CD1a
molecules [94]. More importantly, its action in reversing
the inhibitory effects of VEGF on monocyte-derived DC
maturation and DC-mediated T cell stimulation has also
been demonstrated [95]. The immunomodulatory effects of
sorafenib on monocytes and macrophages have also been
reported to induce autophagy and suppression of human
macrophages [96].
Low doses of antiangiogenic treatment (sorafenib and
sunitinib) have been shown to normalize tumor vasculature
and polarize TAMs, thus reducing immune-regulatory sig-
nals and thereby creating an immune-supportive microen-
vironment for the recruitment and activatation of CD8? T
cells [89]. By this mechanism, low-dose antiangiogenic
treatment enhances the anticancer efficacy of a vaccine
therapy. In contrast, high-dose antiangiogenic treatment
excessively reduces tumor vessels, thus decreasing the
delivery of chemotherapeutics [97, 98]. High-dose antian-
giogenic treatment may also exacerbate, rather than reverse,
the immunosuppressive tumor microenvironment, thus
compromising the efficacy of active cancer immunotherapy.
Therefore, these studies suggest that appropriate low-dose
antiangiogenic treatment could be an effective strategy to
reengineer the tumor microenvironment for active
immunotherapies in a clinical setting.
Conclusions and future perspective
The existence of several tumor-mediated immunosuppres-
sive networks operating in RCC that impede the success of
immune-based therapies is now widely accepted. One of
them involves tumor-induced accumulation of MDSCs
[99].
Emerging data indicate that abnormal tumor vascula-
ture, resulting from the prevalence of proangiogenic factors
over antiangiogenic signals, fosters an immunosuppressive
tumor microenvironment, which in turns enables host
immunosurveillance evasion by the tumor. Proangiogenic
factors not only suppress the function of various immune
cells but also diminish leukocyte–endothelial interactions
and hinder the infiltration of immune effector cells into the
tumor parenchyma.
The induction of high levels of tumor-specific cytotoxic
T lymphocytes is a prerequisite for successful cancer
immunotherapy. Unfortunately, the presence of a high
number of tumor antigen-specific cytotoxic T cells in
peripheral immune organs is associated with little clinical
benefit, so other factors, such as tumor microenvironment,
considered a key player, must be involved in this poor
clinical outcome.
Immunotherapy of mRCC has evolved from a rather
unspecific (e.g. cytokine era) to a more specific (e.g.
checkpoint inhibitors) approach. Immunological check-
points can either inhibit or activate T cells, leading to
speculation as to whether immunomodulation should target
T cell-inhibiting or T cell-activating co-stimulatory mole-
cules. The fact that TKIs can improve type-1 T cell cyto-
kine response while reducing both number and function of
Treg cells, provides a basis for the rational combination of
TKIs and immunotherapy in mRCC.
This mechanism is currently under investigation,
although it is likely to be in part due to MDSC reduction
which inhibits T cell function directly.
Administration of TKIs before vaccination induces
higher antitumor efficacy than post-vaccination or simul-
taneous administration. The modulation of tumor-induced
immunosuppression, which results in a better induction of
antigen-specific CD8? T cells after vaccination, could
explain this synergy. TKIs could normalize tumor vascu-
larization transiently, thus helping CD8? T cell influx into
the tumor after vaccination. Vascular normalization could
also be accompanied by decreased hypoxia. Since hypoxia
seems to be involved in the development of immunosup-
pressive mechanisms, its suppression could represent a
mechanism for modulating tumor-induced
immunosuppression.
CheckMate-025 sub-analyses revealed potential out-
come differences with nivolumab following pazopanib and
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sunitinib, showing only statistically significant increase in
the overall survival only in the case of pazopanib. Taking
this into account, analyzing tumor samples from the PIS-
CES trial would be of great interest to study whether
pazopanib is a better primer compared to sunitinib, before a
second line immunomodulator.
To summarize, rationally scheduled antiangiogenic
treatment can transiently normalize tumor vessels, improve
vessel perfusion, decrease hypoxia and enhance the effi-
cacy of cytotoxic therapies.
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